AMBIGUOUS RESULTS

Tris Pharma says cebranopadol beat placebo on pain in Phase 3 ALLEVIATE-1

The launch of a new pain-drug subsidiary carried the topline result, but Tris Pharma disclosed no effect size, p-value, or safety data behind the win.

By AppliedXLJuly 9, 2026Trial NCT06545097

Executive Summary

Tris Pharma reported that its Phase 3 trial of cebranopadol in acute post-surgical pain met its primary endpoint against placebo, and the company is preparing to file for approval on the strength of that result.
The disclosure described the direction of the effect but did not include the magnitude, statistical strength, or safety detail an investor would need to size the result against existing pain therapies.
Tris Pharma is launching cebranopadol under a dedicated new subsidiary and describing it as a differentiated dual-receptor mechanism meant to rival opioid efficacy while reducing opioid-related risk, a positioning the trial's rescue-medication data support directionally.
No other program identified in this analysis shares cebranopadol's dual NOP/MOP mechanism, so the readout has no direct precedent in this indication and instead sits among a broader field of small-molecule post-surgical analgesics working through different targets.

The catalyst

Tris Pharma said on July 9, 2026 that cebranopadol "demonstrated a reduction in pain compared with placebo over 48 hours" in ALLEVIATE-1, a completed Phase 3 trial of the drug in patients recovering from abdominoplasty. The trial, registered as NCT06545097, enrolled 279 patients under a randomized design with two experimental arms and a placebo comparator. The primary endpoint measured pain intensity on a numeric rating scale, summed as an area-under-the-curve score from 4 to 48 hours post-surgery, against six secondary endpoints including opioid rescue use and time to first rescue dose. The announcement also introduced Adneuris Therapeutics, a Tris Pharma subsidiary formed to develop and commercialize cebranopadol going forward. Tris+1

Probability of Success

Endpoint Met54%

Completes90%

Clinical Significance24%

Regulatory84%

What the release said, and did not

Tris Pharma's chief science and development officer, Jim Potenziano, called the launch part of the company's history of "challenging convention and advancing medicines that address unmet needs". The release reported that cebranopadol reduced opioid rescue medication use compared with placebo and produced a longer time to first rescue dose, alongside the primary pain-reduction result. It did not include the size of the pain-score difference, a p-value, or confidence interval, and it described safety only in general terms rather than reporting an adverse-event profile. Tris Pharma said it anticipates submitting a New Drug Application for cebranopadol in moderate-to-severe acute pain. Tris

Trial conduct

The registry shows a trial that ran on schedule and completed cleanly. The primary completion date moved from April 2025 to December 2024, a pull-forward made in December 2024 while the trial was still active, and the reported enrollment settled at 279 against an earlier anticipated count of 300, a change flagged as typical by the operational model's enrollment-jump threshold. The trial moved to Active-not-recruiting and then to Completed status in the ordinary course, with no gap in registry activity between those transitions. Results have not yet been posted to the ClinicalTrials.gov results database. NCT06545097

The competitive field

Cebranopadol works through both the nociceptin/orphanin FQ (NOP) and mu-opioid (MOP) receptors, a dual mechanism the company describes as intended to preserve opioid-level analgesia while reducing opioid-associated risk. Among post-surgical and acute-pain programs identified in this analysis, none shares that dual-receptor target; comparators such as suzetrigine (Nav1.8), liposomal bupivacaine and ropivacaine (voltage-gated sodium channels), and dezocine and nalbuphine (single opioid receptors) work through different mechanisms, positioning cebranopadol as mechanistically distinct within a small-molecule field of 60 trials recorded in acute pain. That isolation means ALLEVIATE-1's result has no same-mechanism trial to benchmark against; the informative comparison instead runs against the standard-of-care opioid and non-opioid options the company invoked, such as oxycodone, on efficacy and tolerability. Tris

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.